Edmund S. Cibas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edmund S. Cibas has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey F. Krane
David Geffen School of Medicine at UCLA
6 shared publications Justine A. Barletta
Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
5 shared publicationsEllen Marqusee
The Thyroid Section, Division of Endocrinology, Diabetes and Hypertension, the Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts
3 shared publicationsErik K. Alexander
Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
3 shared publicationsJeffrey K. Mito
Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA
3 shared publications- Andrew A. Renshaw
Department of Pathology Baptist Hospital and Miami Cancer Institute Miami Florida USA
2 shared publications
Latest Publications
- 11 September 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (1) , e22903
Cytologic diagnosis of papillary renal neoplasm with reverse polarity
Background: Papillary renal neoplasm with reverse polarity is a recently recognized low‐grade neoplasm with a favorable prognosis. To date, its cytologic features have not been well documented.Methods: Two patients with papillary renal neoplasm with reverse polarity sampled by fine needle aspiration and core needle biopsy are described, one of whom is under active surveillance without clinical progression and the other is alive and well 16 years after partial nephrectomy.Results: The cytologic features included a mix of papillae and dispersed cells with abundant oncocytic cytoplasm and round, bland nuclei apically displaced away from the papillary core. Immunohistochemistry showed positive staining for GATA3 in both cases. Molecular studies on one of the cases showed a KRAS p.G12V mutation.Conclusions: The cytologic features of this distinctive, indolent neoplasm are important to recognize because patients with papillary renal neoplasm with reverse polarity may be excellent candidates for partial nephrectomy or even active surveillance.
- 11 September 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (1) , e22903
Cytologic diagnosis of papillary renal neoplasm with reverse polarity
Background: Papillary renal neoplasm with reverse polarity is a recently recognized low‐grade neoplasm with a favorable prognosis. To date, its cytologic features have not been well documented.Methods: Two patients with papillary renal neoplasm with reverse polarity sampled by fine needle aspiration and core needle biopsy are described, one of whom is under active surveillance without clinical progression and the other is alive and well 16 years after partial nephrectomy.Results: The cytologic features included a mix of papillae and dispersed cells with abundant oncocytic cytoplasm and round, bland nuclei apically displaced away from the papillary core. Immunohistochemistry showed positive staining for GATA3 in both cases. Molecular studies on one of the cases showed a KRAS p.G12V mutation.Conclusions: The cytologic features of this distinctive, indolent neoplasm are important to recognize because patients with papillary renal neoplasm with reverse polarity may be excellent candidates for partial nephrectomy or even active surveillance.
- 9 October 2023
- Published by Wiley in Cancer Cytopathology
- Vol. 132 (4) , 214-223
Validation of targeted next‐generation sequencing of cell‐free DNA from archival cerebrospinal fluid specimens for the detection of somatic variants in cancer involving the leptomeninges: Cytopathologic and radiographic correlation
Background: Leptomeningeal metastases occur across multiple solid and lymphoid cancers, and patients typically undergo cytopathologic assessment of cerebrospinal fluid (CSF) in this setting. For patients diagnosed with metastatic cancer, the detection of actionable somatic mutations in CSF can provide clinically valuable information for treatment without the need for additional tissue collection.Methods: The authors validated a targeted next‐generation sequencing assay for the detection of somatic variants in cancer (OncoPanel) on cell‐free DNA (cfDNA) isolated from archival CSF specimens in a cohort of 25 patients who had undergone molecular testing of a prior tumor specimen.Results: CSF storage time and volume had no impact on cfDNA concentration or mean target coverage of the assay. Previously identified somatic variants in CSF cfDNA were detected in 88%, 50%, and 27% of specimens diagnosed cytologically as positive, suspicious/atypical, and negative for malignancy, respectively. Somatic variants were identified in 81% of CSF specimens from patients who had leptomeningeal enhancement on magnetic resonance imaging compared with 31% from patients without such enhancement.Conclusions: These data highlight the stability of cfDNA in CSF, which allows for cytopathologic evaluation before triage for next‐generation sequencing assays. For a subset of cases in which clinical suspicion is high but cytologic or radiographic studies are inconclusive, the detection of pathogenic somatic variants in CSF cfDNA may aid in the diagnosis of leptomeningeal metastases.
- 9 October 2023
- Published by Wiley in Cancer Cytopathology
- Vol. 132 (4) , 214-223
Validation of targeted next‐generation sequencing of cell‐free DNA from archival cerebrospinal fluid specimens for the detection of somatic variants in cancer involving the leptomeninges: Cytopathologic and radiographic correlation
Background: Leptomeningeal metastases occur across multiple solid and lymphoid cancers, and patients typically undergo cytopathologic assessment of cerebrospinal fluid (CSF) in this setting. For patients diagnosed with metastatic cancer, the detection of actionable somatic mutations in CSF can provide clinically valuable information for treatment without the need for additional tissue collection.Methods: The authors validated a targeted next‐generation sequencing assay for the detection of somatic variants in cancer (OncoPanel) on cell‐free DNA (cfDNA) isolated from archival CSF specimens in a cohort of 25 patients who had undergone molecular testing of a prior tumor specimen.Results: CSF storage time and volume had no impact on cfDNA concentration or mean target coverage of the assay. Previously identified somatic variants in CSF cfDNA were detected in 88%, 50%, and 27% of specimens diagnosed cytologically as positive, suspicious/atypical, and negative for malignancy, respectively. Somatic variants were identified in 81% of CSF specimens from patients who had leptomeningeal enhancement on magnetic resonance imaging compared with 31% from patients without such enhancement.Conclusions: These data highlight the stability of cfDNA in CSF, which allows for cytopathologic evaluation before triage for next‐generation sequencing assays. For a subset of cases in which clinical suspicion is high but cytologic or radiographic studies are inconclusive, the detection of pathogenic somatic variants in CSF cfDNA may aid in the diagnosis of leptomeningeal metastases.
- 28 April 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , 341-350
Degenerative atypia in benign thyroid nodules: a potential diagnostic pitfall on fine-needle aspiration
- 28 April 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , 341-350
Degenerative atypia in benign thyroid nodules: a potential diagnostic pitfall on fine-needle aspiration
- 24 June 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (10) , 824-832
Quantifying the hidden impact of COVID‐19 pandemic: The cytology perspective
Background: The burden of the COVID‐19 pandemic is often enumerated in lives lost, but the strain on health care resources and mobility limitations contributed to the burden of non–COVID related disease. In this study, we evaluated the impact of the pandemic through a time series review of cytology samples.Methods: Pathology reports for all cytology specimens received from January 2019 through April 2021 at our institution were reviewed. Time series analysis was performed using moving averages, time trend analysis, cross‐correlation, and tests of homogeneity.Results: During the first peak of the pandemic (March–June 2020), breakpoint analysis showed a downward shift in the number of gynecologic (−89.4%) and non‐gynecologic (−70.4%) cytology specimens within a week of declaration of an emergency. Cross‐correlation analysis showed a relationship between sample numbers and COVID‐19 cases during the initial phase of the pandemic (April–June 2020). During the second surge (October 2020–April 2021), despite the higher incidence of COVID‐19, there was a smaller impact on cytology samples (−20.1% and − 24.8% for gynecologic and non‐gynecologic samples, respectively). During the first 3 months of the pandemic, 154 fewer malignant cases were identified compared with the prior year. Although specimen numbers slowly returned to baseline following the first wave of the pandemic, the earlier decline in malignant diagnoses was not offset during the study period.Conclusions: The deleterious effects of COVID‐19 extend beyond direct mortality attributed to the disease. The significant decrease in diagnostic cytology specimens during this period has profound implications including delayed care and missed disease.
- 24 June 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (10) , 824-832
Quantifying the hidden impact of COVID‐19 pandemic: The cytology perspective
Background: The burden of the COVID‐19 pandemic is often enumerated in lives lost, but the strain on health care resources and mobility limitations contributed to the burden of non–COVID related disease. In this study, we evaluated the impact of the pandemic through a time series review of cytology samples.Methods: Pathology reports for all cytology specimens received from January 2019 through April 2021 at our institution were reviewed. Time series analysis was performed using moving averages, time trend analysis, cross‐correlation, and tests of homogeneity.Results: During the first peak of the pandemic (March–June 2020), breakpoint analysis showed a downward shift in the number of gynecologic (−89.4%) and non‐gynecologic (−70.4%) cytology specimens within a week of declaration of an emergency. Cross‐correlation analysis showed a relationship between sample numbers and COVID‐19 cases during the initial phase of the pandemic (April–June 2020). During the second surge (October 2020–April 2021), despite the higher incidence of COVID‐19, there was a smaller impact on cytology samples (−20.1% and − 24.8% for gynecologic and non‐gynecologic samples, respectively). During the first 3 months of the pandemic, 154 fewer malignant cases were identified compared with the prior year. Although specimen numbers slowly returned to baseline following the first wave of the pandemic, the earlier decline in malignant diagnoses was not offset during the study period.Conclusions: The deleterious effects of COVID‐19 extend beyond direct mortality attributed to the disease. The significant decrease in diagnostic cytology specimens during this period has profound implications including delayed care and missed disease.
- 4 February 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (5) , 330-335
Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules
BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) are challenging to manage because of their intermediate risk of malignancy. Subclassification of atypia can refine malignancy risk in adult AUS nodules but has not been evaluated in children.METHODS: This was a retrospective cohort study of pediatric patients (P < .001), whereas architectural atypia was not associated with malignancy (P = .8). Repeat FNA was performed in 42 of 68 nodules (62%). In nodules with initial nuclear and architectural atypia, benign repeat cytology had a high false‐negative rate (3 of 6; 50%).CONCLUSIONS: Pediatric AUS nodules with nuclear atypia have a high rate of malignancy, but architectural atypia is not associated with malignancy. In nodules with nuclear atypia, repeat FNA may inform clinical decisions regarding the need for resection. In the absence of suspicious clinical features, nodules without nuclear atypia might be considered for observation rather than resection or repeat FNA.
- 4 February 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (5) , 330-335
Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules
BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) are challenging to manage because of their intermediate risk of malignancy. Subclassification of atypia can refine malignancy risk in adult AUS nodules but has not been evaluated in children.METHODS: This was a retrospective cohort study of pediatric patients (P < .001), whereas architectural atypia was not associated with malignancy (P = .8). Repeat FNA was performed in 42 of 68 nodules (62%). In nodules with initial nuclear and architectural atypia, benign repeat cytology had a high false‐negative rate (3 of 6; 50%).CONCLUSIONS: Pediatric AUS nodules with nuclear atypia have a high rate of malignancy, but architectural atypia is not associated with malignancy. In nodules with nuclear atypia, repeat FNA may inform clinical decisions regarding the need for resection. In the absence of suspicious clinical features, nodules without nuclear atypia might be considered for observation rather than resection or repeat FNA.
- 1 November 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (6) , 535-542
Developing dashboards for performance improvement in cytopathology
- 1 November 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (6) , 535-542
Developing dashboards for performance improvement in cytopathology
- Open Access
- 20 September 2021
- Published by Scientific Scholar in Cytojournal
- Vol. 18, 24-6
CellBlockistry 101: The textbook of cell-blocking science
- 20 September 2021
- Published by Scientific Scholar in Cytojournal
- Vol. 18, 24-6
Open AccessCellBlockistry 101: The textbook of cell-blocking science
- 7 September 2021
- Published by SAGE Publications in Thyroid®
- Vol. 31 (9) , 1441
Re: “The Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysis” by Vuong et al.
- 7 September 2021
- Published by SAGE Publications in Thyroid®
- Vol. 31 (9) , 1441
Re: “The Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysis” by Vuong et al.
- 1 March 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (2) , 113-114
We are minimally invasive diagnosis
- 1 March 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (2) , 113-114
We are minimally invasive diagnosis